Vaxart (Vaxart) Forward Dividend Yield % : 0.00% (As of Apr. 29, 2024)

View and export this data going back to 1990. Start your Free Trial

What is Vaxart Forward Dividend Yield %?

As of today (2024-04-29), the Forward Annual Dividend Yield of Vaxart is 0.00%.

As of today (2024-04-29), the Trailing Annual Dividend Yield of Vaxart is 0.00%.

VXRT's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.475
* Ranked among companies with meaningful Forward Dividend Yield % only.

Vaxart's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Vaxart's Forward Dividend Yield %

For the Biotechnology subindustry, Vaxart's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Vaxart's Forward Dividend Yield % falls into.

Vaxart Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Vaxart (NAS:VXRT) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Vaxart Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Vaxart's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (Vaxart) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

NB11:Germany NB11:Germany

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Executives

W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee	officer: Chief Financial Officer	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron	director	6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg	officer: SVP, General Counsel	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid	director	C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd	officer: VP, Corporate Controller, PAO	3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings	officer: Chief Medical Officer	1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker	officer: Chief Scientific Officer	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour	director, officer: President and Chief Executive	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037